Testosterone Products: Drug Safety Communication - FDA Investigating Risk of Cardiovascular Events

FDA assessing safety issues based on two separate studies that suggested an increased risk of cardiovascular events among groups of men prescribed testosterone therapy.

 
comments powered by Disqus